AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2233283 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame in capsules (20 mg/kg)
Number of subjects: 20
Study 2233283 — intervention group
Group type: COMPARATOR
Intervention: Aspartame in solution (20 mg/kg)
Number of subjects: 20
Study 30806868 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydrug use (both partners exhibited the behavior)
Number of subjects: 320
Study 30806868 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydrug use (only respondent exhibited the behavior)
Number of subjects: 320
Study 30806868 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinking (both partners exhibited the behavior)
Number of subjects: 320
Study 30806868 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinking (only respondent exhibited the behavior)
Number of subjects: 320
Study 28197849 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial therapy in addition to a standard physical therapy program
Number of subjects: 50
Study 28197849 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention in addition to a standard physical therapy program
Number of subjects: 50
Study 28197849 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard physical therapy program (both groups)
Number of subjects: 50
Study 27124003 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate tablets from 2 different Chinese pharmaceutical manufacturers
Number of subjects: 20
Study 27124003 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate tablets
Number of subjects: 20
Study 24325663 — intervention group
Group type: EXPERIMENTAL
Intervention: deproteinized bovine bone mineral (DBBM)
Number of subjects: 38
Study 24325663 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐tricalcium phosphate (β‐TCP)
Number of subjects: 38
Study 24325663 — intervention group
Group type: COMPARATOR
Intervention: Both DBBM and β‐TCP
Number of subjects: 38
Study 22512826 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 364
Study 22512826 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 364
Study 20881359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 26
Study 20881359 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine
Number of subjects: 26
Study 17418968 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of melatonin in the morning (8-9 AM)
Number of subjects: 0
Study 17418968 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of melatonin in the evening (8-9 PM)
Number of subjects: 0
Study 17418968 — intervention group
Group type: COMPARATOR
Intervention: Historical control (whole-brain radiotherapy)
Number of subjects: 0
Study 16599071 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with adjuvant therapy (glycoprotein IIB/IIIA receptor inhibitors and clopidogrel)
Number of subjects: 0
Study 16599071 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolytic agents
Number of subjects: 0
Study 11906689 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-contact intervention (proactive phone contact, motivational interviewing, treatment manual, video, two supportive phone calls)
Number of subjects: 60
Study 11906689 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study 10543294 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzamil (1.7 x 10(‐3) M)
Number of subjects: 10
Study 10543294 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (1 x 10(‐3) M)
Number of subjects: 10
Study 10543294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 10
Study 8749187 — intervention group
Group type: EXPERIMENTAL
Intervention: Sway-referenced visual tests (SOTs 3 + 6)
Number of subjects: 23
Study 8749187 — intervention group
Group type: COMPARATOR
Intervention: Eyes closed tests (SOTs 2 + 5)
Number of subjects: 23
Study 8749187 — intervention group
Group type: EXPERIMENTAL
Intervention: Sway-referenced surfaces (SOTs 4, 5 & 6)
Number of subjects: 23
Study 8749187 — intervention group
Group type: EXPERIMENTAL
Intervention: Sway-referenced support surfaces
Number of subjects: 23
Study 8749187 — intervention group
Group type: EXPERIMENTAL
Intervention: All astronauts
Number of subjects: 23
Study 1978373 — intervention group
Group type: EXPERIMENTAL
Intervention: Benztropine (BZ) at 2 mg i.m. and then 1 mg p.o. b.i.d. for 2 days
Number of subjects: 0
Study 1978373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 383107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pervincamine + glycerol
Number of subjects: 20
Study 383107 — intervention group
Group type: COMPARATOR
Intervention: Glycerol + placebo
Number of subjects: 20
Study 30657186 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (80 mg)
Number of subjects: 24
Study 30657186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28319243 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 7540
Study 28319243 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium
Number of subjects: 7540
Study 28319243 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E and Selenium
Number of subjects: 7540
Study 28319243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7540
Study 25922463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) therapy for six hours per day (n = 74)
Number of subjects: 150
Study 25922463 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual in a plaster cast without IPC (n = 74)
Number of subjects: 150
Study 25922463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) therapy
Number of subjects: 150
Study 25922463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) therapy (n = 74)
Number of subjects: 150
Study 23528027 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (GPIs) during TRA PCI
Number of subjects: 910
Study 21663617 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet-cupping treatment
Number of subjects: 32
Study 21663617 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group
Number of subjects: 32
Study 20180330 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 27
Study 20180330 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 27
Study 18220025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ariphon retard (Servier)
Number of subjects: 81
Study 18220025 — intervention group
Group type: EXPERIMENTAL
Intervention: Prestarium
Number of subjects: 81
Study 18220025 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 81
Study 15671702 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 4029
Study 15671702 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of Hormone Replacement Therapy (HRT)
Number of subjects: 4029
Study 11549228 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking (ad lib)
Number of subjects: 26
Study 11549228 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking abstinence
Number of subjects: 26
Study 11549228 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 26
Study 9199952 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone echocardiography (1 mg/kg over 5 min)
Number of subjects: 10
Study 9199952 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine echocardiography (up to 15 micrograms/kg/min)
Number of subjects: 10
Study 9199952 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone echocardiography
Number of subjects: 10
Study 9199952 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up echocardiogram
Number of subjects: 10
Study 8179735 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg syrup)
Number of subjects: 11
Study 8179735 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent volume)
Number of subjects: 11
Study 3648692 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled supplemental oxygenation (Procedure B)
Number of subjects: 16
Study 3648692 — intervention group
Group type: COMPARATOR
Intervention: No supplemental oxygenation (Procedure A)
Number of subjects: 16
Study 31701481 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab plus lenalidomide and dexamethasone (ELd)
Number of subjects: 82
Study 31701481 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Ld)
Number of subjects: 82
Study 30082359 — intervention group
Group type: EXPERIMENTAL
Intervention: CADL (client-centred activities of daily living)
Number of subjects: 110
Study 30082359 — intervention group
Group type: COMPARATOR
Intervention: UADL (usual activities of daily living)
Number of subjects: 110
Study 28254958 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 61
Study 28254958 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 61
Study 26256964 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal (300 mg, b.i.d.)
Number of subjects: 88
Study 26256964 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (150 mg, b.i.d.)
Number of subjects: 88
Study 24228528 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune 2 plus HAART
Number of subjects: 37
Study 24228528 — intervention group
Group type: COMPARATOR
Intervention: Control group (HIV negative healthy donors)
Number of subjects: 37
Study 21413846 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE problem solving model educational intervention; three conjoint educational sessions during the first month.
Number of subjects: 476
Study 21413846 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 476
Study 18349393 — intervention group
Group type: EXPERIMENTAL
Intervention: FLO (fluorouracil 2,600 mg/m(2) via 24‐hour infusion, leucovorin 200 mg/m(2), oxaliplatin 85 mg/m(2) every 2 weeks)
Number of subjects: 220
Study 18349393 — intervention group
Group type: COMPARATOR
Intervention: FLP (fluorouracil 2,000 mg/m(2) via 24‐hour infusion, leucovorin 200 mg/m(2) weekly, cisplatin 50 mg/m(2) every 2 weeks)
Number of subjects: 220
Study 18349393 — intervention group
Group type: EXPERIMENTAL
Intervention: FLO in patients older than 65 years
Number of subjects: 220
Study 16478005 — intervention group
Group type: EXPERIMENTAL
Intervention: Glomox tablet (test)
Number of subjects: 24
Study 16478005 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin capsule (reference)
Number of subjects: 24
Study 15033211 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone (one meeting with a therapist plus three telephone contacts)
Number of subjects: 28
Study 15033211 — intervention group
Group type: COMPARATOR
Intervention: Group cognitive-behavior therapy (Group)
Number of subjects: 28
Study 15033211 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone
Number of subjects: 28
Study 15033211 — intervention group
Group type: COMPARATOR
Intervention: Group
Number of subjects: 28
Study 11158283 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (1, 3, 6 and 10 ng kg‐1 min‐1)
Number of subjects: 8
Study 11158283 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (10, 30, 60 and 100 ng kg‐1 min‐1)
Number of subjects: 8
Study 11158283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9497755 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based RPD design simulations
Number of subjects: 36
Study 9497755 — intervention group
Group type: COMPARATOR
Intervention: Faculty-led small-group seminars
Number of subjects: 36
Study 8421475 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg per day)
Number of subjects: 122
Study 3321483 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg intravenously before operation
Number of subjects: 40
Study 3321483 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 40
Study 31702047 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g glucose
Number of subjects: 6
Study 31702047 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g glucose
Number of subjects: 6
Study 31702047 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g glucose
Number of subjects: 6
Study 30377184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G5 Mobile continuous glucose monitoring (CGM) system with remote monitoring
Number of subjects: 0
Study 30377184 — intervention group
Group type: COMPARATOR
Intervention: Conventional blood glucose monitoring (control)
Number of subjects: 0
Study 26902618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-clipping injection group (PG)
Number of subjects: 81
Study 26902618 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection group (CG)
Number of subjects: 81
Study 24451883 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implants
Number of subjects: 155
Study 24451883 — intervention group
Group type: COMPARATOR
Intervention: Delayed loaded implants
Number of subjects: 155
Study 24451883 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless surgical technique
Number of subjects: 155
Study 24451883 — intervention group
Group type: COMPARATOR
Intervention: Full-thickness flap technique
Number of subjects: 155
Study 22176029 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate RNA isolation after tooth extraction
Number of subjects: 15
Study 22176029 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nitrogen (24 h)
Number of subjects: 15
Study 22176029 — intervention group
Group type: EXPERIMENTAL
Intervention: -80 °C (24 h)
Number of subjects: 15
Study 22176029 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 °C (24 h)
Number of subjects: 15
Study 22176029 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 °C (6 h)
Number of subjects: 15
Study 21246922 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, 0.15 mg/kg every 6 hours for 4 days
Number of subjects: 147
Study 21246922 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with dexamethasone)
Number of subjects: 147
Study 19026268 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI)
Number of subjects: 2875
Study 16189969 — intervention group
Group type: EXPERIMENTAL
Intervention: SVD-based optimal filtering technique
Number of subjects: 0
Study 16189969 — intervention group
Group type: COMPARATOR
Intervention: Adaptive beamformer
Number of subjects: 0
Study 12594304 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 908-htrA high dose (4.5 x 10(8) CFU)
Number of subjects: 8
Study 12594304 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 908-htrA low dose (5 x 10(7) CFU)
Number of subjects: 8
Study 12594304 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 908-htrA (both doses)
Number of subjects: 8
Study 11783226 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Xiansu Capsule (CXSC) combined with chemotherapy
Number of subjects: 61
Study 11783226 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 61
Study 7502997 — intervention group
Group type: EXPERIMENTAL
Intervention: Workers cognizant of the study
Number of subjects: 1088
Study 7502997 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day recall period
Number of subjects: 1088
Study 7502997 — intervention group
Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 1088
Study 7502997 — intervention group
Group type: COMPARATOR
Intervention: Overall SBS prevalence
Number of subjects: 1088
Study 2681676 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthrinse (Peridex)
Number of subjects: 40
Study 2681676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30785844 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexDex (FD)
Number of subjects: 22
Study 30785844 — intervention group
Group type: COMPARATOR
Intervention: Standard Laparoscopy (SL)
Number of subjects: 22
Study 27876583 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative stabilization by pediatric orthopedists (Group A)
Number of subjects: 88
Study 27876583 — intervention group
Group type: COMPARATOR
Intervention: Operative stabilization by non-pediatric orthopedists (Group B)
Number of subjects: 88
Study 25498417 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (40 mg)
Number of subjects: 30
Study 25498417 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (75 mg)
Number of subjects: 30
Study 25498417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24094274 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatments (specific types not detailed)
Number of subjects: 0
Study 24094274 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 21897859 — intervention group
Group type: EXPERIMENTAL
Intervention: Subway air exposure in healthy individuals
Number of subjects: 64
Study 21897859 — intervention group
Group type: EXPERIMENTAL
Intervention: Subway air exposure in asthmatics
Number of subjects: 64
Study 21897859 — intervention group
Group type: COMPARATOR
Intervention: Ambient air exposure
Number of subjects: 64
Study 19682661 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 3-12 mg/d capsules
Number of subjects: 1018
Study 19682661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1018
Study 17430256 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% captopril gel
Number of subjects: 56
Study 17430256 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% captopril gel
Number of subjects: 56
Study 17430256 — intervention group
Group type: COMPARATOR
Intervention: placebo gel
Number of subjects: 56
Study 11160953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg/d
Number of subjects: 30
Study 11160953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 25 mg/d
Number of subjects: 30
Study 11160953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 50 mg/d
Number of subjects: 30
Study 11160953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 100 mg/d
Number of subjects: 30
Study 11160953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9951857 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (5-fluorouracil 200 mg/m2, doxorubicin 15 mg/m2, mitomycin 5 mg/m2)
Number of subjects: 83
Study 9951857 — intervention group
Group type: COMPARATOR
Intervention: Control group (palliative surgery only)
Number of subjects: 83
Study 8310507 — intervention group
Group type: EXPERIMENTAL
Intervention: 33B3.1 monoclonal antibody (10 mg/day)
Number of subjects: 40
Study 8310507 — intervention group
Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin (ATG) (1.5 mg/kg/day)
Number of subjects: 40
Study 8310507 — intervention group
Group type: EXPERIMENTAL
Intervention: 33B3.1 monoclonal antibody
Number of subjects: 40
Study 8310507 — intervention group
Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin (ATG)
Number of subjects: 40
Study 3747335 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (prednisolone) at an initial dose of 60 mg/24 hr for 8 weeks
Number of subjects: 89
Study 3747335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 89
Study 29747597 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity group (14 sessions of treadmill exercise and physical activity consultations)
Number of subjects: 784
Study 29747597 — intervention group
Group type: COMPARATOR
Intervention: Usual care (six-weekly sessions of smoking cessation behavioural-support)
Number of subjects: 784
Study 27449894 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 0
Study 24457911 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-DT (epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab)
Number of subjects: 102
Study 24457911 — intervention group
Group type: COMPARATOR
Intervention: EC-DL (epirubicin plus cyclophosphamide followed by docetaxel plus lapatinib)
Number of subjects: 102
Study 24457911 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-DT
Number of subjects: 102
Study 24457911 — intervention group
Group type: COMPARATOR
Intervention: EC-DL
Number of subjects: 102
Study 23307525 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-pharmacist collaborative intervention
Number of subjects: 496
Study 23307525 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 496
Study 19922458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 244
Study 19922458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 19032914 — intervention group
Group type: EXPERIMENTAL
Intervention: Early use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers
Number of subjects: 0
Study 18249214 — intervention group
Group type: EXPERIMENTAL
Intervention: New American Diabetes Association definition for impaired fasting glucose (IFG)
Number of subjects: 1034
Study 18249214 — intervention group
Group type: COMPARATOR
Intervention: Initial fasting plasma glucose (FPG) values <100 mg/dL
Number of subjects: 1034
Study 18249214 — intervention group
Group type: COMPARATOR
Intervention: Initial fasting plasma glucose (FPG) values 100 to 109 mg/dL
Number of subjects: 1034
Study 18249214 — intervention group
Group type: COMPARATOR
Intervention: Initial fasting plasma glucose (FPG) values 110 to 125 mg/dL
Number of subjects: 1034
Study 18249214 — intervention group
Group type: EXPERIMENTAL
Intervention: New definition of IFG including persons with FPG 100 to 109 mg/dL
Number of subjects: 1034
Study 18249214 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose levels from 64 to 125 mg/dL
Number of subjects: 1034
Study 15204121 — intervention group
Group type: EXPERIMENTAL
Intervention: Item recognition test (Experiments 1, 3a, and 4)
Number of subjects: 0
Study 15204121 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative recency decision task (Experiments 2, 3b, and 5)
Number of subjects: 0
Study 11420590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular betamethasone 12 mg
Number of subjects: 171
Study 11420590 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone 50 mg daily for seven days
Number of subjects: 171